Español
In the last days of the year, it is time to review everything we have done so far and plan for the coming months. The year 2022 has been very special for Oligofastx, because after the start date in October 2021 and the final resolution of CDTI on December 28, 2021, the project has become […]
Author Archives: oligofastx
22
Dec
Dec
The Oligofastx project covers all areas, from start to finish, of the process of developing oligonucleotides to fight several specific diseases: from design and preclinical research to production. Therefore, in this consortium, all the partners contribute their experience and knowledge in specific areas of action, thus completing a clear, consistent, coherent and results-oriented strategy. All […]
16
Dec
Dec
There is no doubt that oligonucleotide therapies aimed at providing answers and improving the quality of life of patients with certain rare diseases, which still have no solution, are a hopeful prospect. The path, already started with numerous initiatives, Oligofastx among them, is also a reality. But much research remains to be done, not only […]
International Biotechnology Day 2024, Uncategorized
Oligonucleotides, the language of life in small doses
12
Dec
Dec
A technological revolution can start with a key concept, the application of an equation or, often, with the development of a particular material. Steels, alloys, concretes, liquid fuels, semiconductors or polymers are examples that changed the history of mankind and today are ubiquitous in our lives. The pharmaceutical industry is no different. Thus, the ability […]
28
Nov
Nov
The Oligofastx project covers the different phases of the development of oligonucleotide-based therapies, from design to production, and this is one of the reasons why the consortium is made up of seven companies, each specializing in different phases of the process. Today we talk about solid-phase synthesis. Oligonucleotides are short chains of different “building blocks” […]
25
Nov
Nov
OLIGOFASTX follows with great interest all the recent advances in the work with oligonucleotides, not only in terms of new lines of research, but also with respect to all the applications that are being developed close to the market. Because it is our ultimate goal and our objective: to provide solutions to diseases that do […]
07
Nov
Nov
History is peppered with stories, legends and tales. And as in all of them, any biography of a person of international relevance, such as the one we are dealing with today, is full of anecdotes, joys and sorrows and betrayals. Recognizing all his valuable contributions, the life of Maurice Wilkins is marked by destiny: the […]
26
Oct
Oct
Thyroid cancer is a common malignancy of the endocrine system. There are four types: Papillary thyroid cancer is the most common of all thyroid cancers. Follicular thyroid cancer accounts for 10% of thyroid cancers. Medullary thyroid cancer represents 2% of thyroid cancers. Anaplastic thyroid cancer is the most advanced and aggressive of the thyroid cancers. […]
20
Oct
Oct
Today we are going to talk about one of those diseases classified as rare, for which there is, as yet, no solution. It is one of the diseases we are working on and researching at Oligofastx: Guillain-Barré syndrome. Guillain-Barré syndrome (GBS) is a neurological disorder in which the body’s immune system attacks the peripheral nervous […]
Nobel Prize
The Most Excellent Nobel Laureates 2022: these were the winners in the categories of Chemistry and Medicine
06
Oct
Oct
The work of the most renowned scientists, artists and diplomats is rewarded every year at this time thanks to the Nobel Prizes. And the whole of society, but especially the scientific community, is always on the lookout to find out who wins such a distinguished title. Once again this year, we congratulate ourselves for the […]